[Skip to Content]
[Skip to Content Landing]
Viewpoint
June 19, 2018

Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Author Affiliations
  • 1Department of Clinical Pharmacy, University of California, San Francisco
  • 2Center for Translational and Policy Research on Personalized Medicine, San Francisco, California
  • 3Philip R. Lee Institute for Health Policy, University of California, San Francisco
  • 4Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
JAMA. 2018;319(23):2379-2380. doi:10.1001/jama.2018.4863

Reimbursement has been cited as a key barrier to the adoption of precision medicine into clinical care.1 This issue has recently attracted attention with the March 2018 Centers for Medicare & Medicaid Services (CMS) national coverage determination on next-generation sequencing tests for patients with advanced cancer.2

×